Parenteral nutrition-associated cholestasis
MONDO:0035777A rare hepatic disease characterized by intrahepatic cholestasis and deterioration of liver function in patients receiving parenteral nutrition for extended periods of time (signs may appear as early as within the first two weeks of initiation of parenteral nutrition). The condition commonly occurs in neonates and usually resolves with transition to enteral feeding, although severe cases may progress to liver fibrosis, cirrhosis, and portal hypertension.
Also known as: PNAC
12 clinical trials for this condition and its sub-types, 5 tagged with Parenteral nutrition-associated cholestasis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Fish oil treatment tested for kids with liver damage from IV nutrition
Disease control Recruiting nowThis study is testing the safety of Omegaven, a fish oil-based fat emulsion, in 40 children under 18 who have developed liver problems (cholestasis) from long-term IV nutrition. The main goal is to see how many children develop essential fatty acid deficiency during at least 8 we…
Sponsor: Fresenius Kabi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New study checks if IV fat emulsion prevents nutrient shortages in Long-Term patients
Disease control Recruiting nowThis study looks at how safe SMOFlipid is for children and adults who need IV nutrition for 8 weeks or more. It checks if the treatment causes a lack of essential fats or liver problems. About 100 participants will be followed to see how their bodies respond.
Phase 4 • Sponsor: Fresenius Kabi • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC